At what enterprise value was OTTOBOCK acquired in 2025?

During the acquisition of OTTOBOCK by PUBLIC MARKETS (IPO) in 2025, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 3b - 100b EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of OTTOBOCK when it was acquired by PUBLIC MARKETS (IPO)?

The estimated EV/EBITDA multiple for OTTOBOCK is in the range of 15x - 25x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was OTTOBOCK acquired by PUBLIC MARKETS (IPO)?

OTTOBOCK was acquired by PUBLIC MARKETS (IPO) in 2025.

What was the revenue of OTTOBOCK at the time of the deal?

The revenue of OTTOBOCK at the time of the deal is estimated to be in the range of 1b - 3b EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of OTTOBOCK during the acquisition?

OTTOBOCK's EBITDA is estimated to be in the range of 250M - 500M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the OTTOBOCK acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the OTTOBOCK deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.eqs-news.com/news/media/ottobock-celebrates-successful-ipo-in-frankfurt/d1e0aab8-a74b-406e-b17c-cbce31248402_en

← DATABASE

Home Database Healthcare & PharmaOTTOBOCK

10/2025

OTTOBOCK acquired by PUBLIC MARKETS (IPO)

GERMANY Life Sciences / Medical Devices / Implants & Prosthetics EV 3b - 100b EUR

Context

Ottobock successfully completed its Initial Public Offering on the Frankfurt Stock Exchange, marking the largest German IPO of 2025. The shares were priced at €66.00, with the first trading price reaching €72.00 (a 9% premium). At the issue price, the market capitalization stood at €4.2 billion, rising to €4.6 billion upon listing. The strategic rationale for the IPO was to raise gross proceeds to deleverage the balance sheet and accelerate investments in "future technologies," such as AI-integrated bionics and exoskeleton research. Additionally, the capital will fund targeted acquisitions in the fragmented Patient Care and components sectors. The deal marks a milestone in the company’s history, professionalizing its capital structure while providing an exit path for previous minority stakeholders and securing a long-term capital base for global expansion.

In the past, the company underwent an LBO led by Eqt Partners in 2017, and continued an active consolidation strategy by notably acquiring Matton Orthomedi (2025).

OTTOBOCK, which reported an EBITDA margin of LOGIN in 2024, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Ottobock is the global market leader in wearable human bionics and prosthetics. Its business model integrates the development and manufacturing of high-tech mobility solutions—including bionic prostheses, braces, and wheelchairs—with a vast global "Patient Care" network of over 400 fitting centers. The company’s value proposition centers on restoring human mobility through innovation, such as the microprocessor-controlled C-Leg and the Genium bionic knee. Strategically, Ottobock operates a vertically integrated model, capturing value from R&D and component manufacturing to direct clinical service delivery. With over 9,300 employees, the firm has evolved from a traditional family business into a data-driven medtech powerhouse, focusing on digitalizing the orthopedic fitting process and expanding its presence in emerging markets.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2024

2023

Other operations with OTTOBOCK

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
05/2025	OTTOBOCK	MATTON ORTHOMEDI	BELGIUM	Life Sciences	In May 2025, Ottobock, through its subsidiary Vigo, acquired Matton OrthoMedi as part of its strategy to consolidate the European technical orthopedics market. The primary objective of this acquisition is to strengthen Ottobock's network of care centers in Western Europe by integrating a well-established local player in Belgium. Matton OrthoMedi brings a established network of locations in Ghent, Bruges, and Brussels, as well as over 30 years of expertise in orthopedic care and custom device manufacturing, catering to patients with complex mobility needs
06/2017	EQT PARTNERS	OTTOBOCK	GERMANY	Life Sciences	EQT VII has entered into an agreement to acquire a 20% minority stake in Ottobock, as part of a strategic partnership aimed at supporting Ottobock's international growth ambitions, driving its strategic objectives, and potentially preparing the company for a future initial public offering (IPO) in the medium term. The investment by EQT comes at a time of significant transformation in the mobility technology market, driven by an aging population, increasing demand for rehabilitation solutions, and advancements in smart prosthetics

REFERENCES

Valuation range: EV 3b - 100b EUR

Revenue range: 1b - 3b EUR

EBITDA range: 250M - 500M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of OTTOBOCK by PUBLIC MARKETS (IPO) are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Target: ottobock